Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the Chilean population

Arab, Juan Pablo; Hernández-Rocha, Cristian; Morales, Carolina; Vargas, José Ignacio; Solı́s, Nancy; Pizarro, Margarita; Robles, Camila; Sandoval, Daniela; Ponthus, Simon; Benítez, Carlos; Barrera, Francisco; Soza, Alejandro; Riquelme, Arnoldo; Arrese, Marco

doi:10.1016/j.gastre.2017.02.003

Cited by 8 publications

(8 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because CK-18 is mainly produced by caspase 3, which has been found to be active in NASH liver [30], serum CK-18 may be elevated in patients with NASH. This suggests that CK-18 could be used as a biomarker that reflects the degree of NAFLD fibrosis [31][32][33][34][35][36]. Here, serum CK-18 in the low-CK-18 NAFLD group was not significantly different from that of the non-NAFLD group in a population diagnosed using ultrasound, suggesting that ultrasound may not be ideal for the pathological grading of fibrosis in NAFLD patients.…”

Section: Discussionmentioning

confidence: 96%

Non-alcoholic fatty liver disease, cytokeratin-18, and risk of type 2 diabetes mellitus: A cohort study

Shu

Han³

et al. 2019

Preprint

View full text Add to dashboard Cite

Background & Aims: Although many studies have shown that non-alcoholic fatty liver disease (NAFLD) is associated with type 2 diabetes mellitus (T2DM), no cohort study has explored the relationship between the histopathological grade of NAFLD and the risk of T2DM in NAFLD patients. We aimed to explore whether a higher concentration of cytokeratin-18 (CK-18), as a reliable marker of hepatic fibrosis, was associated with a greater risk of T2DM in patients with NAFLD. Methods: The population-based cohort study was based on China National Diabetes and Metabolic Disorders Survey with a follow-up of five years. NAFLD was determined by ultrasonography. T2DM were diagnosed based on oral glucose tolerance test. Serum CK-8 was measured using the M30 Apoptosense ELISA kit. Results: 457 subjects were enrolled and three groups were analyzed: a non-NAFLD group (n=363), a low-CK-18 NAFLD group (n=46), and a high-CK-18 NAFLD group (n=48). 20 (3.9%) developed diabetes during follow-up. The incidence of T2DM was 2.5%, 8.7%, and 12.5% in the non-NAFLD, low-CK-18 NAFLD, and high-CK-18 NAFLD groups, respectively. Cox proportional hazard regression showed that, compared with the non-NAFLD group, the adjusted relative risks of T2DM were 3.37 (95% CI: 1.05-10.86, P =0.042) and 4.71 (95% CI: 1.71-12.99, P =0.003), respectively, in the low-CK-18 NAFLD and high-CK-18 NAFLD groups. Conclusions: Higher CK-18 level in ultrasound-diagnosed NAFLD patients is associated with higher risk of T2DM. We recommend screening for NAFLD using ultrasound in the first instance, with, if possible, CK-18 assay being subsequently used to screen individuals at higher risk of diabetes.

show abstract

Section: Discussionmentioning

confidence: 96%

Non-alcoholic fatty liver disease, cytokeratin-18, and risk of type 2 diabetes mellitus: A cohort study

Shu

Han³

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Plasma stored at -80 °C was used for quantitative measurement of CK-18 levels by the Human cytokeratin ELISA kit (MJS Biolynx inc, Brockville Ontario, Canada). A cut-off of CK-18 > 130.5 U/L was used to indicate significant hepatocyte apoptosis, diagnostic for NASH when combined with CAP > 270 dB/m[ 25 , 26 ]. Liver fibrosis (stage ≥ 1 out of 4) was diagnosed as LSM ≥ 7.4 kPa[ 16 ].…”

Section: Methodsmentioning

confidence: 99%

Non-alcoholic steatohepatitis in liver transplant recipients diagnosed by serum cytokeratin 18 and transient elastography: A prospective study

Alhinai¹,

Qayyum-Khan²,

Zhang³

et al. 2021

WJH

View full text Add to dashboard Cite

BACKGROUND Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) seem common after liver transplantation. AIM To investigate incidence and predictors of NAFLD and NASH by employing noninvasive testing in liver transplant recipients, namely controlled attenuation parameter (CAP) and the serum biomarker cytokeratin 18 (CK-18). We also evaluated the diagnostic accuracy of CK-18 and CAP compared to liver histology. METHODS We prospectively recruited consecutive adult patients who received liver transplant at the McGill University Health Centre between 2015-2018. Serial measurements of CK-18 and CAP were recorded. NAFLD and NASH were diagnosed by CAP ≥ 270 dB/m, and a combination of CAP ≥ 270 dB/m with CK-18 > 130.5 U/L, respectively. Incidences and predictors of NAFLD and NASH were investigated using survival analysis and Cox proportional hazards. RESULTS Overall, 40 liver transplant recipients (mean age 57 years; 70% males) were included. During a median follow-up of 16.8 mo (interquartile range 15.6-18.0), 63.0% and 48.5% of patients developed NAFLD and NASH, respectively. On multivariable analysis, after adjusting for sex and alanine aminotransferase, body mass index was an independent predictor of development of NAFLD [adjusted hazard ratio (aHR): 1.21, 95% confidence interval (CI): 1.04-1.41; P = 0.01] and NASH (aHR: 1.26, 95%CI: 1.06-1.49; P < 0.01). Compared to liver histology, CAP had a 76% accuracy to diagnose NAFLD, while the accuracy of CAP plus CK-18 to diagnose NASH was 82%. CONCLUSION NAFLD and NASH diagnosed non-invasively are frequent in liver transplant recipients within the first 18 mo. Close follow-up and nutritional counselling should be planned in overweight patients.

show abstract

“…Hepatocyte apoptosis plays a critical role in the pathogenesis of NAFLD 15 . In the early stages of apoptosis, caspases cut epithelium-specific intermediate filament cytokeratin 18 (CK18) into 3 fragments 16,17 .…”

Section: Introductionmentioning

confidence: 99%

“…In the early stages of apoptosis, caspases cut epithelium-specific intermediate filament cytokeratin 18 (CK18) into 3 fragments 16,17 . Recent studies have shown that CK18 is a good biomarker for NASH 15,18,19 . Irisin has protective effects on the liver by reducing lipogenesis and lipid accumulation and stimulating glycogenesis 20 .…”

Section: Introductionmentioning

confidence: 99%

Non-alkolik yağlı karaciğer hastalığında kafein alımı ve karaciğer biyobelirteçleri arasındaki ilişki

Uçar

KAHRAMANOĞLU

Göktaş

2023

Cukurova Medical Journal

View full text Add to dashboard Cite

Purpose: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of elevated liver enzymes in developed countries. The aim of this study is to examine the effects of caffeine intake on some parameters of liver metabolism in individuals with NAFLD. Materials and Methods: A total of 20 female and 20 male subjects between the ages of 19 to 64, who were diagnosed with NAFLD, were included in the study. To determine caffeine intake, a specially developed caffeine-food frequency questionnaire was administered by a trained dietitian. Individuals were categorized into 3 groups according to their caffeine intake; Group 1: ≤150 mg/day, Group 2: 150-250 mg/day, and Group 3: ≥250 mg/day. Anthropometric measurements and biochemical parameters were recorded. Protein quantities in serum samples were determined by ELISA method. Results: The body fat composition of group 1 was higher than group 2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels of group 3 were higher than group 1 and group 2, respectively. High-density lipoprotein cholesterol (HDL-C) level of group 3 was lower than group 1 and group 2. There was a positive correlation between total caffeine intake and ALT level. There was no significant difference between the caffeine intake groups in terms of serum protein levels. In addition, there was not found significant correlation between serum protein levels and total caffeine intake. Conclusion: Caffeine intake of ≥250 mg/day may increase ALT and AST levels and decrease HDL-C level in individuals with NAFLD.

show abstract

Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the Chilean population

Cited by 8 publications

References 34 publications

Non-alcoholic fatty liver disease, cytokeratin-18, and risk of type 2 diabetes mellitus: A cohort study

Non-alcoholic fatty liver disease, cytokeratin-18, and risk of type 2 diabetes mellitus: A cohort study

Non-alcoholic steatohepatitis in liver transplant recipients diagnosed by serum cytokeratin 18 and transient elastography: A prospective study

Non-alkolik yağlı karaciğer hastalığında kafein alımı ve karaciğer biyobelirteçleri arasındaki ilişki

Contact Info

Product

Resources

About